Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Royalty Pharma
Pharma
Teva taps Royalty to bankroll long-acting schizophrenia drug
Royalty Pharma has gained potential royalties to Teva's long-acting antipsychotic, olanzapine LAI, for up to $125 million.
Angus Liu
Nov 13, 2023 11:40am
Royalty commits up to $1.5B for most of PTC's Evrysdi royalties
Oct 19, 2023 11:13am
Royalty Pharma strikes $150M Skytrofa royalty deal with Ascendis
Sep 6, 2023 11:28am
Royalty strikes $500M deal with Ferring on new gene therapy
Aug 24, 2023 10:46am
'The Top Line': The most productive pharmas, Biogen's leadership
Oct 14, 2022 6:00am
Theravance, Ultragenyx sell royalties for $1.8B
Jul 14, 2022 11:48am